Next Article in Journal
Kinome-Wide Screening with Small Interfering RNA Identified Polo-like Kinase 1 as a Key Regulator of Proliferation in Oral Cancer Cells
Previous Article in Journal
Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects
Open AccessCommunication

Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study

by Yang-Xun Pan 1,2,†, Mian Xi 1,3,†, Yi-Zhen Fu 1,2,†, Dan-Dan Hu 1,2, Jun-Cheng Wang 1,2, Shi-Liang Liu 1,3, Jin-Bin Chen 1,2, Li Xu 1,2, Zhong-Guo Zhou 1,2, Meng-Zhong Liu 1,3, Min-Shan Chen 1,2, Lei Zhao 1,3 and Yao-Jun Zhang 1,2,*
1
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
2
Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
3
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
*
Author to whom correspondence should be addressed.
The first three authors contributed equally to this work.
Cancers 2019, 11(8), 1116; https://doi.org/10.3390/cancers11081116
Received: 5 July 2019 / Revised: 19 July 2019 / Accepted: 23 July 2019 / Published: 5 August 2019
Abstract: (1) Background: To investigate the clinical outcomes between radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) for residual hepatocellular carcinoma (RHCC). (2) Methods: 139 patients were diagnosed with the RHCC after post-operative checkup, among whom 39 and 33 patients underwent RFA or SBRT as salvage treatments, respectively. We applied the propensity score matching (PSM) to adjust for imbalances in treatment assignment. Local disease progression, progression-free survival (PFS), overall survival (OS), and treatment-related side effects were the study endpoints. (3) Results: Before PSM, the SBRT group demonstrated significantly lower local disease progression rate (6/33 vs. 23/39; p = 0.002), better PFS (the 1- and 3-year PFS were 63.3% and 49.3% vs. 41.5% and 22.3%, respectively, p = 0.036), and comparable OS (the 1- and 3-year OS were 85.4% and 71.1% vs. 97.3% and 57.6%, respectively, p = 0.680). After PSM of 23 matched cases, the SBRT group demonstrated significantly lower local disease progression rate, better PFS and comparable OS. Centrally located tumor predicted the worse OS. No acute grade 3+ toxicity was observed in both groups. (4) Conclusion: SBRT might be the preferred treatment for RHCC, especially for patients with larger tumors or tumors abutting major vessels, rather than repeated RFA. View Full-Text
Keywords: stereotactic body radiotherapy; radiofrequency ablation; hepatocellular carcinoma; propensity score matching stereotactic body radiotherapy; radiofrequency ablation; hepatocellular carcinoma; propensity score matching
Show Figures

Figure 1

MDPI and ACS Style

Pan, Y.-X.; Xi, M.; Fu, Y.-Z.; Hu, D.-D.; Wang, J.-C.; Liu, S.-L.; Chen, J.-B.; Xu, L.; Zhou, Z.-G.; Liu, M.-Z.; Chen, M.-S.; Zhao, L.; Zhang, Y.-J. Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study. Cancers 2019, 11, 1116.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop